Author:
Tolaney Sara M.,Guarneri Valentina,Seo Jae Hong,Cruz Josefina,Abreu Miguel Henriques,Takahashi Masato,Barrios Carlos,McIntyre Kristi,Wei Ran,Munoz Maria,Antonio Belen San,Liepa Astra M.,Martin Miguel,Johnston Stephen R.D.,Kellokumpu-Lehtinen Pirkko-Liisa,Harbeck Nadia
Reference18 articles.
1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020
2. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial;Johnston;Lancet Oncol,2023
3. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study;Harbeck;Ann Oncol,2021
4. VERZENIOS™ (abemaciclib) European Medicines Agency. 2022. Amsterdam, Netherlands: European Medicines Agency. 〈https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios〉.
5. FDA expands early breast cancer indication for abemaciclib with endocrine therapy, March 3. 2023 〈https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy〉.